1. Synergistic anticancer efficacy of polydatin and sorafenib against the MCF-7 breast cancer cell line via inhibiting of PI3K/AKT/mTOR pathway and reducing resistance to treatment.
- Author
-
Donia T, Ali EMM, Kalantan AA, Alzahrani FA, Eid TM, and Khamis AA
- Subjects
- Humans, MCF-7 Cells, Phosphatidylinositol 3-Kinases metabolism, Female, Antineoplastic Agents pharmacology, Cell Proliferation drug effects, Apoptosis drug effects, Molecular Docking Simulation, Hep G2 Cells, Proto-Oncogene Proteins c-akt metabolism, Stilbenes pharmacology, Drug Synergism, Sorafenib pharmacology, TOR Serine-Threonine Kinases metabolism, Drug Resistance, Neoplasm drug effects, Glucosides pharmacology, Signal Transduction drug effects, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Breast Neoplasms pathology
- Abstract
Polydatin (PD), a glucoside derivative of resveratrol, has been investigated for its potential to mitigate sorafenib (SOF) side effects and combat multidrug resistance in cancer treatment. The study evaluated its mechanism of action for inhibiting the protein kinase B/mTOR pathway in promoting breast cancer proliferation. The combined PD and SOF have synergistic effects with a combination index (CI) < 1 in the liver (HepG2) and breast (MCF-7) cancer cell lines. Molecular docking studies were conducted to analyze interactions of PD& SOF with protein kinases as well as apoptotic and multidrug resistance proteins, including AKT1, PI3K, mTOR, Apaf-1, and ABCB1 in MCF-7 cells. Experimental validation through real-time PCR confirmed. PD has a strong binding affinity, particularly with AKT1 (-56 kcal/mol) and ABCB1 (-27.16 kcal/mol), a gene associated with multidrug resistance. These interactions were linked to anti-proliferative anti-angiogenic effects and reduced resistance to treatment, demonstrating PD has potential therapeutic benefits. Furthermore, PD combined with SOF induced apoptosis, inhibited cell growth, and arrested MCF-7 cells in the sub-G1 phase with increased intracellular ROS. This was accompanied by reduced expression of AKT1 and ABCB1 genes, reinforcing the anticancer efficacy of PD/SOF combination therapy. In conclusion, the findings suggest that PD/SOF could serve as a promising anticancer treatment strategy, warranting further investigation for potential clinical applications and mechanistic studies in vivo., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Abeer Abdel Hamid Khamis reports was provided by Tanta University Faculty of Science. Abeer Abdel Hamid Ahmed Khamis reports a relationship with Tanta University Faculty of Science that includes: employment. Abeer Abdel Hamid Khamis has patent #1 pending to 1111. The authors declare that they have agreed to the publication of this work., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF